# Women's Estrogen/Progestin Lipid Lowering Hormone Atherosclerosis Regression Trial (WELL-HART)

> **NCT00000559** · PHASE3 · COMPLETED · sponsor: **National Heart, Lung, and Blood Institute (NHLBI)**

## Conditions studied

- Cardiovascular Diseases
- Coronary Disease
- Heart Diseases
- Myocardial Ischemia
- Postmenopause

## Interventions

- **DRUG:** estrogen replacement therapy
- **DRUG:** hormone replacement therapy
- **DRUG:** estradiol
- **DRUG:** medroxyprogesterone

## Key facts

- **NCT ID:** NCT00000559
- **Lead sponsor:** National Heart, Lung, and Blood Institute (NHLBI)
- **Sponsor class:** NIH
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1995-03
- **Primary completion:** —
- **Final completion:** 2001-08
- **Target enrollment:** — (—)
- **Last updated:** 2016-07-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00000559

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00000559, "Women's Estrogen/Progestin Lipid Lowering Hormone Atherosclerosis Regression Trial (WELL-HART)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00000559. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*